CGTLive®’s Weekly Rewind – August 2, 2024

CGTLive®’s Weekly Rewind

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Pfizer Drops Development of DMD Gene Therapy Fordadistrogene Movaparvovec

The program’s cancellation follows a previous announcement that its phase 3 trial had missed its primary end point.

2. Joshua M. Hare, MD, on Promising Data on Lomecel-B for Alzheimer Disease

The cofounder and chief science officer of Longeveron discussed updated data from the phase 2a CLEAR MIND study.

3. New Study Recommends Shorter, Flexible Monitoring After CAR T-Cell Therapy

There were no new cases of CRS past 2 weeks after infusion and non-relapse mortality was driven by infection in follow-up.

4. Chris Wright, MD, PhD, on Anelloviruses, a Potential Alternative to AAV for Gene Therapy

The chief medical officer and head of translational research at Ring Therapeutics discussed research presented at ASGCT 2024.

5. Umoja Biopharma's In Situ CAR-T Therapy Cleared for US Trial in Hematologic Malignancies

The trial will be open to patients with relapsed/refractory large-B-cell lymphoma and chronic lymphocytic leukemia.